Funder: Breakthrough T1D
Due Dates: October 31, 2024 (Letter of Intent) | January 7, 2025 (Full proposal)
Funding Amounts: Up to $2,000,000 over 3 years for clinical trials; up to $1,000,000 over 3 years for non-interventional studies; 10% indirect costs allowed (non-profit only)
Summary: Supports clinical trials and mechanistic studies advancing metabolic therapies for established type 1 diabetes by repurposing treatments from other metabolic diseases.
Key Information: LOI required before full proposal; both academic and industry applicants eligible; no citizenship restrictions.